Medical/Pharmaceuticals
/C O R R E C T I O N -- Akeso, Inc./
In the news release, Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline, issued 21-Aug-2026 by Akeso, Inc. over PR Newswire, we are advised by the company that there are some amendments in the "About AK157D1" section. The compl...
WuXi Biologics Reports Strong Profitable Growth in H1 2026
* Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD) * IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds * EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted...
Fosun Pharma Announces 2026 Interim Results
Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company r...
MATELASER Unveils MATEROBOT®, a Next-Generation Six-Axis Laser Therapy Robot With a Detachable Portable Laser System
Powered by the FDA-cleared X1 PERFORMANCE ULTRA, the modular platform combines robotic automation, triple-wavelength laser therapy and closed-loop thermal control MIAMI, Aug. 25, 2026 /PRNewswire/ -- MATELASER, INC., a U.S.-based developer of advanced laser therapy and rehabilitation technologie...
Innovent Announces 2026 Interim Results and Business Updates
Transforming from Regional Leader to Global Premier: A Clear Strategic Path for Growth and Globalization SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and comm...
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
BEIJING, Aug. 25, 2026 /PRNewswire/ -- On August 25, Haisco Pharmaceutical Group Co., Ltd.("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners ("PHP") and ARCH Venture Partners (...
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
TAIPEI, Aug. 25, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombinati...
Classys Nears 50,000 Devices Sold Globally as Full-Lineup Growth Accelerates
* Expands global portfolio beyond HIFU and MRF to include MNRF, laser, and dermabrasion devices, strengthening its medium- to long-term growth foundation * 1H26 Exports, excluding shipments to its Brazilian subsidiary, grew 29% year over year, underscoring continued growth across global market...
Dimora Medical Introduces New Pricing for MegaSorb™ Dressings, Expanding Access to Professional-Grade Wound Care
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Dimora Medical, a continuous innovator in high-end medical care supplies, today announced price reductions across its entire MegaSorb™ wound dressing lineup—with select SKUs discounted by up to 29% to make advanced wound management solutions more accessible...
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
* Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] basis) * Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increas...
ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
* Development of Leptin receptor-based technology and hybrid LNP platform * Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics * Technology validated by winning first place in...
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
* HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity * Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...
Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
NEW YORK, Aug. 23, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administ...
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innov...
LumenStim Prepares to Launch Next-Generation Teeth Whitening System on Kickstarter
Kickstarter-approved LumenStim Teeth Whitening System
Coreline Soft and INFINITT North America Deploy Chest CT-Based AI Reading Workflow at St. Joseph's Health
PHILLIPSBURG, N.J. and ATLANTA, Aug. 21, 2026 /PRNewswire/ -- Coreline Soft,
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based o...
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed att...
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Op...
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZE...
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 276 media titles]
2026-09-29 09:00Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30